Latest Articles
March 2, 2017
RNA Labs—How they Impact the Medical World
By having the ATG Lab at Ambry, it is possible to further refine VUS results and look beyond DNA in order to determine the benign…
BRCA1 & 2
Genetic Testing
Variant of Unknown Significance
VUS
February 16, 2017
Scientific Research Consent Made Easy
Now anyone can participate in a scientific research study through AmbryShare’s simplified consent process.
AmbryShare
Clinical Research
HBOC
New England Journal of Medicine
February 6, 2017
Genetic Testing Accuracy Explained During the AmbrySpeaks-Los Angeles Event
Genetic Testing Accuracy Explained During the AmbrySpeaks-Los Angeles Event
Ambry Speaks Tour
AmbryShare
BRCA2
PALB2
Sanger Confirmation
February 2, 2017
Exome Sequencing Provides More Coverage Than You Think
New research suggests that whole exome sequencing (WES) offers similar base pair coverage to MGPT for Mendelian diseases.
Mendelian diseases
Multigene Panel Testing
Next Generation Sequencing
Novel Genes
University of California-Irvine
Whole Exome Sequencing
January 18, 2017
AmbrySpeaks’ Tour kicks off in Los Angeles
Ever since our initial publication of Sanger sequencing confirmation was featured in The Journal of Molecular Diagnostics, in addition to our accompanying presentation at the…
Ambry Speaks Tour
AmbryShare
Genetic Testing
Sanger Confirmation
December 23, 2016
New Research on Male Breast Cancer: Unexpected Results and Insights
Ambry Genetics, Huntsman Cancer Institute and Mayo Clinic conduct largest reported study of men with breast cancer undergoing multi-gene panel testing.
BRCA1 & 2
CHEK2
Huntsman Cancer Institute
Male Breast Cancer
Mayo Clinic
PALB2